Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.
Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6.
Mesenchymal stem cells are mobilized from the bone marrow during inflammation.
Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis.
Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians.
[Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs].
TRPM2 Cation Channels Modulate T Cell Effector Functions and Contribute to Autoimmune CNS Inflammation.
[Therapy adherence to immunomodulator treatment in patients with multiple sclerosis].
No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis.
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.
NDRG2 promoted secreted miR-375 in microvesicles shed from M1 microglia, which induced neuron damage.
Neuromuscular adaptations to long-term progressive resistance training translates to improved functional capacity for people with multiple sclerosis and is maintained at follow-up.
Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability.
Utilization and patients' perceptions of the effectiveness of pain treatments in multiple sclerosis: A cross-sectional survey.
Spinal Cord Normalization in Multiple Sclerosis.
The role of complement in inflammatory diseases from behind the scenes into the spotlight.
Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter.
Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab.
Axon-glia interaction and membrane traffic in myelin formation.
[Local reactions to disease-modifying drugs: pathogenesis and relationship to clinical effectiveness.]
Proteasome Inhibitors: A New Perspective for Treating Autoimmune Diseases.
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.
[Assessment of the size of the thalamus as a method for the evaluation of the activity of neurodegenerative process after the treatment with cerebrolisin in young patients with multiple sclerosis.]
[Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"]
Anti-interleukin-2 receptor alpha for multiple sclerosis?

Pages